Mobile

A randomized, active-controlled, open-label, multicenter cross-over study with two 6-week treatment periods to investigate the effect of the combination of Lescol XL (fluvastatin) 80 mg and fenofibrat...

Update Il y a 4 ans
Reference: EUCTR2006-002007-13

A randomized, active-controlled, open-label, multicenter cross-over study with two 6-week treatment periods to investigate the effect of the combination of Lescol XL (fluvastatin) 80 mg and fenofibrate 200 mg on HDL-C in comparison to the combination of simvastatin 20 mg and ezetimibe 10 mg in patients with metabolic syndrome

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To confirm that the combination of fluvastatin 80 mg extended release (ER) and fenofibrate 200 mg has superior efficacy in increasing HDL-C compared with the combination of simvastatin 20 mg and ezetimibe 10 mg after a treatment period of 6 weeks each in patients with type 2 diabetes/metabolic syndrome

Inclusion criteria

  • Dyslipidaemia

Links